Using a preclinical glioma model, we demonstrate that CCR2+/CX3CR1+ cells are sourced from the bone marrow, suppress both CD4+ and CD8+ T cells, migrate to CCL2 and/or CCL7 in a CCR2-dependent manner, and are reduced in the glioma microenvironment through combination targeting of CCL2 and CCL7. The gene discussed is CCL7; the disease is glioma.